Transdermal Delivery of Vaccines and Therapeutic Proteins - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Transdermal Delivery of Vaccines and Therapeutic Proteins
The author reviews advances in technology that may soon allow transdermal delivery of two of the fastest growing drug classes on the pharmaceutical market. This article is part of a special Drug Delivery issue.


Pharmaceutical Technology
pp. s14-s20

24. V. I. Kaledin et al., JNCI 66 (5), 881–887 (1981).

25. C. Oussoren and G. Storm, Adv. Drug Deliv. Rev. 50, 143–156 (2001).

26. A. Supersaxo, W. R. Hein, and H. Steffen, Pharm. Res. 7 (2), 167–169 (1990).

27.. A. J. Harvey et al., Pharm. Res. (2010), http://www.springerlink.com/content/j227p875h614x3w4/, accessed Oct. 13, 2010.

28 J. Gupta, E. I. Felner, and M. R. Prausnitz, Diabetes Technol. Ther. 11 (6), 329–337 (2009).

29. F. Cosman et al., J. Clin. Endocrinol. Metab., 95, 151–158, (2010).

30. C. A. Frolik et al., Bone 33, 372–379 (2003).

31. L. A. Denson, Expert Opin. Drug Metab. Toxicol. 4 (12), 1569–1580 (2008).

32. T. Karpanen, and K. Alitalo, Journal of Experimental Medicine 194(6), F37–F42 (2001).

33. Y. Xie, T. R. Bagby, M. S. Cohen, and M. L. Forest, Expert Opinion on Drug Delivery 6(8), 785–792 (2009).

34. L. T. Kuhn, P. L. Pieto, and B. Wen, Cancer Research 69, 2135 (2009).

35. A. Arora, M. R. Prausnitz, and S. Mitagotri, Intern. Jrnl. of Pharmaceut. 364, 227–236 (2008)

36. S. A. Frech et al., The Lancet 341, 2019–2025 (2008).

37. G. M. Glenn et al., Vaccines 6 (5), 809–819 (2007).

38. S. Garg et al., Clin. Vaccine Immunol. 14( 7), 926-928 (2007).

39. A. C. Sintov et al., Jrnl. Control. Rel. 89 (2), 311–320 (2003).

40. M. M. Badran, J. Kuntsche, and A. Fahr, Eur. J. Pharm. Sci. 36 (4–5), 511–523 (2009).


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
27%
Oversee medical treatment of patients in the US.
12%
Provide treatment for patients globally.
8%
All of the above.
46%
No government involvement in patient treatment or drug development.
7%
Jim Miller Outsourcing Outlook Jim MillerCMO Industry Thins Out
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerFluorination Remains Key Challenge in API Synthesis
Marilyn E. Morris Guest EditorialMarilyn E. MorrisBolstering Graduate Education and Research Programs
Jill Wechsler Regulatory Watch Jill Wechsler Biopharma Manufacturers Respond to Ebola Crisis
Sean Milmo European Regulatory WatchSean MilmoHarmonizing Marketing Approval of Generic Drugs in Europe
Seven Steps to Solving Tabletting and Tooling ProblemsStep 1: Clean
Legislators Urge Added Incentives for Ebola Drug Development
FDA Reorganization to Promote Drug Quality
FDA Readies Quality Metrics Measures
New FDA Team to Spur Modern Drug Manufacturing
Source: Pharmaceutical Technology,
Click here